Samsung Biologics

Aktuelle Nachrichten

Schlagzeilen in der Originalsprache der Quelle.

• 삼성바이오로직스, 국내외 제약바이오 4개 행사 참여 (öffnet in neuem Tab)

  바이오스펙테이터 · 01.10.2026

• Samsung Biologics Labor Talks Break Down Again, Union Signals Possible Collective Action (öffnet in neuem Tab)

  알파경제 · 01.10.2026

• ₩1,550,655 저항선에서 돌파를 시도하는 Samsung Biologics 주식: 주목할 상승 목표 (öffnet in neuem Tab)

  Traders Union · 01.10.2026

• Samsung Biologics Redefines Biopharmaceuticals: 3.5-Month Development Time Reduction Revealed at BPI 2026 (öffnet in neuem Tab)

  뉴스1 · 29.09.2026

• 
  Samsung Biologics publishes prospectus for PolyPeptide public tender offer (öffnet in neuem Tab)

  PR Newswire · 31.08.2026

• 
  Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion (öffnet in neuem Tab)

  PR Newswire · 27.08.2026

• 
  Samsung Biologics Reports Second Quarter 2026 Financial Results (öffnet in neuem Tab)

  PR Newswire · 22.07.2026

• 
  Samsung Biologics: geographic diversification is a sound business decision (öffnet in neuem Tab)

  Pharmaceutical Technology · 22.07.2026

• 
  Samsung Biologics to acquire PolyPeptide in $1.81bn cash deal (öffnet in neuem Tab)

  Pharmaceutical Technology · 20.07.2026

• 
  Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker (öffnet in neuem Tab)

  BioPharma Dive · 20.07.2026

• 
  Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India (öffnet in neuem Tab)

  PR Newswire · 19.07.2026

• South Korea Centrifugation Market: Focus on Product, Model Type, Application, and End User - Analysis and Forecast, 2025-2035 Published; Maps Biopharm Manufacturing Demand (öffnet in neuem Tab)

  09.07.2026

• 
  Samsung Biologics Releases 2026 ESG Report, Highlighting Progress in Sustainable Operations and Responsible Growth (öffnet in neuem Tab)

  PR Newswire · 30.06.2026

• Pharma’s manufacturing reconfigurations provide CDMOs with expansion opportunities (öffnet in neuem Tab)

  12.05.2026

• 
  Samsung Biologics Listed on Dow Jones Best-in-Class World Index for Fifth Consecutive Year (öffnet in neuem Tab)

  PR Newswire · 05.05.2026

• 
  Samsung Biologics Reports First Quarter 2026 Financial Results (öffnet in neuem Tab)

  PR Newswire · 22.04.2026

• 
  Samsung Biologics acquires GSK’s facility in Maryland, US (öffnet in neuem Tab)

  Investment Monitor · 01.04.2026

• 
  Samsung Biologics completes acquisition of GSK's manufacturing facility in Rockville, Maryland (öffnet in neuem Tab)

  PR Newswire · 31.03.2026